Browsing by Subject "malignant and benign haematology"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Acute lymphoblastic leukaemia with osteolytic bone lesions: diagnostic dilemma
    (BMJ, 2018-08-11) Angsubhakorn, Natthapon; Suvannasankha, Attaya; Medicine, School of Medicine
    A previously healthy 37-year-old man presented with a 10-month history of intractable back pain. On examination, there was tenderness to palpation along lower thoracic and lumbar spine. Complete blood count showed mild anaemia but was otherwise unremarkable. Imaging studies revealed compression deformities with multiple osteolytic lesions involving multiple levels of the thoracic and lumbar spine. Bone marrow aspiration and biopsy were performed and demonstrated blast cells involving 80% of the bone marrow cellularity. Findings on flow cytometry were consistent with B-lymphoblastic leukaemia. He was subsequently started on hyper-CVAD (fractionated cyclophosphamide, vincristine, Adriamycin and dexamethasone) induction chemotherapy.
  • Thumbnail Image
    Item
    Cold agglutinin-mediated autoimmune haemolytic anaemia associated with diffuse large B cell lymphoma
    (BMJ, 2018-07-10) Wongsaengsak, Sariya; Czader, Magdalena; Suvannasankha, Attaya; Medicine, School of Medicine
    Cold agglutinin-mediated autoimmune haemolytic anaemia is associated with the development of autoantibodies that can agglutinate red blood cells at cold temperatures. While primary cold agglutinin disease is an idiopathic lymphoproliferative disorder, secondary cold agglutinin syndrome (CAS) complicates other diseases such as infections, autoimmune diseases and cancers, mostly low-grade lymphomas. Early recognition, treatment of CAS and treatment of its associated underlying diseases are crucial to a successful outcome. We report a case of CAS in a setting of diffuse large B cell lymphoma, in which the treatment course was complicated by worsened anaemia due to chemotherapy-induced myelosuppression. We reviewed previously reported cases and discussed diagnosis and treatment strategies, including novel complement inhibitors, as potential future therapy.